{"title":"与抗肿瘤检查点抑制剂治疗相关的关节病:目前对该问题的理解","authors":"A. D. Koltakova, A. M. Lila","doi":"10.14412/1996-7012-2023-5-112-117","DOIUrl":null,"url":null,"abstract":"Checkpoint inhibitors (CPI) are anticancer drugs that activate the immune response against cancer cells. This type of treatment is highly effective, but also associates with many immunoinflammatory complications, including musculoskeletal. This review presents the current understanding of the clinical manifestations, pathogenesis and therapy of immune-mediated arthropathy in patients receiving CPI.","PeriodicalId":270571,"journal":{"name":"Sovremennaâ Revmatologiâ","volume":"75 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"2023-10-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Arthropathy associated with antitumor checkpoint inhibitors therapy: current understanding of the problem\",\"authors\":\"A. D. Koltakova, A. M. Lila\",\"doi\":\"10.14412/1996-7012-2023-5-112-117\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Checkpoint inhibitors (CPI) are anticancer drugs that activate the immune response against cancer cells. This type of treatment is highly effective, but also associates with many immunoinflammatory complications, including musculoskeletal. This review presents the current understanding of the clinical manifestations, pathogenesis and therapy of immune-mediated arthropathy in patients receiving CPI.\",\"PeriodicalId\":270571,\"journal\":{\"name\":\"Sovremennaâ Revmatologiâ\",\"volume\":\"75 1\",\"pages\":\"0\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2023-10-18\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Sovremennaâ Revmatologiâ\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.14412/1996-7012-2023-5-112-117\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Sovremennaâ Revmatologiâ","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.14412/1996-7012-2023-5-112-117","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Arthropathy associated with antitumor checkpoint inhibitors therapy: current understanding of the problem
Checkpoint inhibitors (CPI) are anticancer drugs that activate the immune response against cancer cells. This type of treatment is highly effective, but also associates with many immunoinflammatory complications, including musculoskeletal. This review presents the current understanding of the clinical manifestations, pathogenesis and therapy of immune-mediated arthropathy in patients receiving CPI.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
